WSGR logoWSGR logo
Kenneth A. Clark
Partner
Corporate
Palo Alto
San Diego

D650-320-4742

Download vCard
LinkedIn
Open PDF
  • Experienced Legal Advisor to Biotech Companies

    Ken acts as outside general counsel to biotechnology companies and their boards of directors.

  • Substantial Transactions Experience

    Ken has negotiated more than 100 major strategic alliance and M&A transactions. In addition to partnering agreements and strategic transactions, Ken represents companies in financings, spin-outs, and other deals.

  • A Recognized Practitioner

    Ken has been recognized in Chambers USA as one of the top biotechnology attorneys in the U.S.

Ken Clark serves as general counsel to companies and their boards of directors, primarily in the biotechnology industry. Ken has extensive expertise in partnering and strategic transactions, having negotiated more than 100 major strategic alliance and M&A transactions. He also regularly represents companies in financings, spin-outs, and related matters.

Ken served on the firm's board of directors from 2011 to 2014 and from 2002 to 2006, and previously was a member of the firm's Policy Committee. Ken served as a director of Pharmacyclics, Inc. (NASDAQ: PCYC) from 2012 until their sale to AbbVie in 2015.

Experience

Ken Clark serves as general counsel to companies and their boards of directors, primarily in the biotechnology industry. Ken has extensive expertise in partnering and strategic transactions, having negotiated more than 100 major strategic alliance and M&A transactions. He also regularly represents companies in financings, spin-outs, and related matters.

Ken served on the firm's board of directors from 2011 to 2014 and from 2002 to 2006, and previously was a member of the firm's Policy Committee. Ken served as a director of Pharmacyclics, Inc. (NASDAQ: PCYC) from 2012 until their sale to AbbVie in 2015.

Focus Areas
Recent Insights
News Articles
IFLR1000 Recognizes Wilson Sonsini Practices, Attorneys in 2024 Guide
In the 2024 edition of its annual guide, IFLR recognized Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors in the U.S. and China. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.
Learn More
Client Highlights
Wilson Sonsini Advises Dren Bio on Collaboration with Novartis
On July 24, 2024, Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform. Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction.
Learn More
View All
WSGR logo
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.